HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Lowers Price Target to $95
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio maintains a 'Buy' rating on Vir Biotechnology (NASDAQ:VIR) but lowers the price target from $100 to $95.
August 07, 2023 | 10:08 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite the lowered price target, Vir Biotechnology maintains a 'Buy' rating from HC Wainwright & Co.
The lowered price target might cause some short-term uncertainty among investors, potentially impacting the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100